Similarly, 24-week HFCFD-fed CebpaΔHep,ERT2 mice treated with tamoxifen for the last 12 weeks, developed enhanced liver fibrosis while scAAV8-U6-shSpp1 rescued the hepatocyte CEBPA deficiency-enhanced liver fibrosis (Figure 6, G–K) without changing other biochemical parameters (Supplemental Figure 7D). This evidence concerns the gene MAPK3 and Hepatic fibrosis.